



PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF NOVEL ANTIBIOTICS IN THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS

Dr. Uttam Prasad Panigrahy¹

¹Associate Professor, Department of Pharmaceutical Analysis, Faculty of Pharmaceutical sciences, Assam down town University, Sankar Madhab Path, Gandhi Nagar, Panikhaiti, Guwahati, Assam, India, uttampanigrahy@gmail.com

Dr. Prarthana Srivastava²

²Associate Professor, KIET group of institutions, Delhi NCR, Ghaziabad, prarthana.srivastava@kiet.edu

Dr Sneh Agrawal³

³Associate professor, Department of periodontology, Bharati Vidyapeeth (deemed to be university) dental college and hospital, Navi Mumbai , sneh.agrawal@bharatividyaapeeth.edu

Dr Anand Konkala⁴

⁴Associate professor of Zoology, Govt City College, Osmania University, Hyderabad, konkala27@gmail.com

Dr Vivek Sharma⁵

⁵Assistant Professor, Department of Periodontology , Bharati Vidyapeeth (deemed to be university) dental college and hospital, Navi Mumbai, vivek.sharma@bharatividyaapeeth.edu

Sumanta Bhattacharya⁶

⁶Research scholar, Department of textile technology, MAKAUT, Westbengal, sumanta.21394@gmail.com

Article History: Received: 01.02.2023

Revised: 07.03.2023

Accepted:

10.04.2023

Abstract

In critically sick patients, it is difficult to determine the ideal regimens for new beta-lactam/lactamase inhibitors (BLBLIs). Gram-negative bacteria that are multidrug-resistant (MDR) and increase mortality in infected people are a serious challenge to world healthcare. As the danger of antimicrobial obstruction has developed and antimicrobial improvement has eased back, mind boggling and thorough pharmacokinetic and pharmacodynamic studies have progressed over a brief timeframe. The objective of the ongoing examination is to investigate the disturbing issue of anti-infection obstruction and the making of bacterial strains that are impervious to many medications, the two of which are currently common in emergency clinics and represent a danger to the overall work to control irresistible sicknesses. The motivation behind this study was to distinguish the best BLBLI treatments for these patients.

Keywords: Gram-negative bacteria infection, pharmacokinetic, pharmacodynamic, Multi drug resistance, novel antibiotics.

INTRODUCTION

The World Wellbeing Association records anti-infection resistance as one of the main 10 dangers to worldwide wellbeing. Each 2019, around 2.8 million anti-infection safe illnesses happen in the US, prompting more than 35,000 fatalities, as revealed by the Habitats for Infectious prevention and Counteraction. Half of the over 2.8 million cases of sickness can be attributed to Gram-negative organisms, namely enter bacteria that generate broad-spectrum lactamases (10 of the 18 threats found in the CDC survey).

Yet, few new antimicrobial agents have been developed to treat these illnesses, despite the continued increase in incidence, morbidity, and death associated with these infections. 2014 Beginning around 2012, only nine prescriptions focusing on Gram-negative infection resistance have been authorized, and 78% of significant drug organizations have diminished or decreased speculation for anti-microbial exploration because of troubles being developed. Stopping. Several of these difficulties can be attributed to factors such as limited resources, the infeasibility of conducting clinical trials, strict regulations, and meager results. Since drug resistance increases and new medications are not being developed quickly enough, pharmacokinetic (PK) and pharmacodynamics (PD) research are becoming increasingly critical for sustaining and improving already existing treatments. The field of pharmacodynamics (PD) investigates the connection between drug concentration and effect at the site of action, while the field of pharmacokinetics analyzes the rate at which drugs are absorbed, distributed, metabolized, and eliminated. Antibiotics are unique among pharmaceutical medications because they may kill non-target species. The dose-response relationship can be better defined when PK and PD are taken into account together. This is a critical stage in increasing a drug's usefulness and

decreasing its side effects for the benefit of patients.

With the advent of stringent PK/PD methodologies and a deeper appreciation for the significance of dosage optimization, the development of antibacterial drugs has been completely transformed. By eliminating a lack of attention on planning in the preparation stages of Stages II and III, we may save expenses, enhance predictability of adequacy and disability, decrease damage, and lessen disappointment in clinical evaluations. Avoided. Post-marketing antibiotic regimens may be adjusted and individualized for specific patient groups with the use of these cutting-edge PK/PD approaches, such as B. PK display in a population. B. Very sick. In this article, we discuss how antimicrobial drug development is dynamic, how PK/PD readings are important, and how PK/PD has played a part in both significant triumphs and failures. I attempted The United States' ever-changing regulatory landscape and the slow but steady advancement in antibiotic PK/PD science.

LITERATURE REVIEW

Bhavnani et al., 2020 In result, legislation was gradually developed to close these loopholes in the medication advancement process. The European Meds Organization (EMA), the US Food and Drug Organization (FDA), and other administrative bodies generally gave tough rules for the legitimate direct of Stage III exploration on antibacterial drugs in 2002. Many large pharmaceutical companies abandoned research and development of antibacterial medications in response to the restrictions. Companies of a smaller scale saw an opportunity to fill this void and make some money, but they lacked the resources of the larger ones and found it difficult to communicate the difference between a synthetic and a revelation, so they lost interest in developing new antibiotics.

Luepke and Mohr, 2017 Over the last ten years, there has been a renaissance in interest in and monetary and administrative help for the review and creation of novel anti-biotics as a result of the tremendous public health repercussions of a lack of antimicrobial innovation. Government organizations and significant public-private partnerships, such BARDA and CARB-X, began to incentivise the antibiotic industry, accelerating the discovery and commercialization of additional antimicrobials.

Rizk et al., 2019 The discovery of the relevance of pharmacology in translational medicine coincided with the resurgence of interest in the development of antimicrobial drugs, particularly given the challenges associated with concluding extensive, demanding clinical trials in the field of battling resistant Gram-negative infections. In the cutting edge time of antimicrobial turn of events, PK/PD information are integrated into the methodology from the beginning to help with grasping medication systems of activity, picking the best lead compounds, supporting dose selection, minimizing the use of animals, speeding up the development process, estimating the therapeutic index, and providing more assurance before larger, more expensive, and time-consuming clinical trials.

Gallo, 2010 Pharmacometrics and model-based drug improvement terms spread generally, and the study of anti-toxin PK/PD meticulousness extended quickly. Pharmacometrics uses PK and PD data to produce models depicting parts of prescription viability like sickness movement, therapy adherence, and bacterial turn of events, fully intent on giving direction in beginning arrangement, practicality relationships, segment improvement, and decisions in regards to mind in a particular patient populace. Ultimately, administrative bodies like the FDA and others began to focus on the impacts of PK/PD also. They changed their industry direction to urge backers to

construct a strong groundwork in PK/PD and gain an exhaustive comprehension of how to upgrade the utilization of their medication well before entering Stage 3 clinical preliminaries. Preceding the adjustment of accentuation toward PK/PD research, PK and PD were frequently inspected independently with no administrative direction on how these investigations ought to be completed. The FDA required studies to include PK parameters but did not specify how these factors related to PD traits.

As expressed by a few creators Trivedi et al., 2013, Enhancements in pharmacometrics have assisted with laying out the job of PK/PD during the time spent drug improvement by diminishing expenses and accelerating the prescription endorsement process.

It has been shown that Because of the critical requirement for antimicrobial drugs to treat safe Gram-negative infections, administrative organizations stand out on PK/PD information to assist antimicrobials with accomplishing market endorsement. The FDA held a studio in 2016 to examine issues and underscore the requirement for these specific antibacterial drugs. The IDSA released a white paper in response to this workshop that provided an overview of several techniques for clinical preliminary plan and information bundles, including PK/PD information, on the side of the development of novel antimicrobial agents.

MATERIALS AND METHODS

A. PK Parameters

While the PK characteristics of MV were investigated in an adult patient trial, no studies involving critically ill patients were found. The collected data included clearance, volume of distribution, and AUC₂₄, and it was given as mean standard deviation.

B. PD Data

Pseudomonas aeruginosa and Enterobacteriaceae are the most well-known microbes that lead to GNB

infections (*Escherichia coli*, *Klebsiella pneumoniae*).

RESULTS

A. Probability of Three Novel BLBLIs Achieving Their Target Attainments

Data demonstrated that individuals who underwent conventional regimens had a combined PTA of three new BLBLIs.

B. Cumulative Fraction of Responses

Tables 1, 2, and 3 displayed the new BLBLI regimens' CFRs.

Table 1. Ceftazidime/avibactam cumulative proportion of responses for *Pseudomonas aeruginosa* and *Enterobacteriaceae*.

Dose (mg)	CFR 50% CA				CFR 100% CA			
	2 h	3 h	4 h	Continuous Infusion	2 h	3 h	4 h	Continuous Infusion
<i>Escherichia coli</i>								
200/500 q8h	90.31%	92.65%	93.70%	93.11%	84.54%	89.44%	90.00%	92.35%
250/25 q8h	91.51%	93.08%	93.25%	93.25%	86.42%	90.96%	91.64%	92.78%

<i>Klebsiella pneumoniae</i>								
200/500 q8h	84.58%	86.60%	87.00%	87.06%	77.36%	81.71%	83.33%	86.45%
200/500 q6h	86.95%	87.09%	87.12%	87.10%	85.22%	86.92%	88.08%	85.84%
250/25 q6h	87.66%	87.72%	87.74%	87.13%	86.61%	86.55%	86.81%	87.01%
<i>Pseudomonas aeruginosa</i>								
200/500 q8h	80.28%	87.74%	87.73%	87.60%	75.83%	80.42%	81.27%	84.23%
200/500 q6h	88.88%	88.88%	88.88%	88.62%	84.11%	88.44%	88.52%	86.07%

	6 %	6 %	2 %		6 %	8 %	1 %	
250/625 q8h	82.0 %	89.0 %	89.0 %	89.47 %	73.5 %	82.0 %	83.2 %	86.23 %
250/625 q6h	90.0 %	90.0 %	90.0 %	90.41 %	86.25 %	88.0 %	87.3 %	87.85 %

Table 2. Percentage of patients who experienced adverse reactions to ceftolozane/tazobactam for Enterobacteriaceae and Pseudomonas aeruginosa over time.

Dose (mg)	CFR 40% CA				CFR 100% CA			
	1 h	3 h	4 h	Continuous Infusion	1 h	3 h	4 h	Continuous Infusion
Esc herichia coil								
100/500 q8h	98.72 %	98.9 %	99.0 %	99.00 %	92.11 %	95.1 %	96.9 %	98.35 %
125/250 q8h	98.3 %	99.1 %	99.1 %	99.16 %	93.3 %	96.0 %	97.2 %	98.60 %

Klebsiella pneumoniae								
100/500 q8h	80.78 %	81.28 %	81.38 %	81.26 %	70.9 %	73.7 %	75.2 %	78.45 %
100/500 q6h	80.6 %	81.1 %	81.8 %	81.66 %	71.1 %	76.6 %	77.7 %	79.22 %
125/250 q8h	81.7 %	82.8 %	82.5 %	82.44 %	73.3 %	75.0 %	76.7 %	79.35 %
125/250 q6h	83.59 %	83.44 %	83.5 %	83.12 %	77.0 %	78.1 %	79.4 %	80.32 %
Pseudomonas aeruginosa								
100/500 q8h	86.9 %	86.3 %	86.9 %	86.74 %	69.9 %	73.3 %	75.5 %	84.42 %
100/500 q6h	83.2 %	80.57 %	77.4 %	71.51 %	73.9 %	75.1 %	74.0 %	70.35 %

125 0/6 25 q8h	8 6. 7 2 %	8 7. 1 6 %	8 7. 1 7 %	87. 15 %	7 1. 3 5 %	7 7. 1 1 %	7 9. 2 7 %	85. 46 %
125 0/6 25 q6h	8 6. 6 2 %	8 6. 1 0 %	8 3. 4 4 %	82. 80 %	7 9. 9 1 %	8 2. 6 8 %	8 1. 2 2 %	81. 72 %

Table 3. Total percentage of responses to meropenem/vaborbactam in patients with enterobacteriaceae and pseudomonas aeruginosa

Dose (mg)	CFR45% MV			CFR 100% MV		
	3h	4h	5h	3h	4h	5h
Esche richia coil						
2000/ 2000 q8h	97. 48 %	97. 49 %	97. 49 %	95. 37 %	96. 52 %	97. 10 %
2500/ 2500 q8h	99. 24 %	99. 24 %	99. 24 %	97. 64 %	98. 23 %	98. 95 %
Klebs iella pneu moni ea						
2000/ 2000 q8h	96. 44 %	96. 60 %	96. 65 %	91. 98 %	93. 78 %	94. 70 %
2500/ 2500 q8h	98. 52 %	98. 64 %	98. 78 %	94. 66 %	95. 61 %	96. 83 %
Pseud omon as aerug inosa						

2000/ 2000 q8h	94. 04 %	94. 98 %	95. 30 %	75. 11 %	79. 50 %	82. 86 %
2000/ 2000 q6h	95. 87 %	95. 84 %	96. 08 %	86. 40 %	88. 47 %	91. 71 %
2500/ 2500 q8h	97. 04 %	97. 65 %	98. 09 %	79. 63 %	82. 70 %	86. 67 %
2500/ 2500 q6h	98. 38 %	98. 61 %	98. 52 %	89. 14 %	91. 86 %	94. 88 %

DISCUSSION

Despite the positive potential of using new antibacterial drugs, research have shown that certain GNB exhibited novel BLBLI resistance. A portion of the mentioned materials were shown to be resistant to new BLBLIs, according to the distribution of MIC given in this research. Additionally, severely sick patients' dramatically changed PK of new BLBLIs. Therefore, in critically sick patients, it is crucial to optimize their regimens. For Escherichia coli, the standard regimen only met the target CFRs100%CTCFRsCT100%, while for Klebsiella pneumoniae, all regimens fell short of the PK/PD goals. The unfavorable outcomes of Klebsiella pneumoniae might be attributed to this isolate's resistance mechanism, which includes the formation of ESBL and oxacillinase, which tazobactam was unable to suppress. Our research has other drawbacks as well. (1) MV PK investigations in very unwell individuals have not yet been published. The pharmacokinetic information for the MV utilized in MCS came from grown-up patients. When contrasted with preliminaries of fundamentally debilitated people with extreme sepsis and septic shock, in any case, meropenem's pharmacokinetics were comparative. Vaborbactam is mostly eliminated through the kidneys. About 90% PTA was achieved with the conventional vaborbactam regimen. The PK/PD goal of vaborbactam

will rise, nevertheless, since renal failure may occur in a large number of critically sick patients. Therefore, severely sick individuals may still benefit from our findings. (2) More clinical studies are required to confirm the effectiveness and safety of greater doses and lengthier infusions, in spite of the way that MCS is an important device for recognizing satisfactory experimental anti-toxin measurement regimens at public and provincial levels.

CONCLUSION

Research has advanced significantly, with a rise in the number of novel antibiotics that are effective against Gram-negative bacteria. For pathogens on the WHO's 2016 list of critical priority, high priority, and medium priority pathogens, the majority of drugs authorized and under clinical development from 2017 to the present day combine a β -lactam inhibitor. Along with the drug known as SPR-206 phase I, cefiderocol is the only antibiotic that is effective against all three infections of essential importance. In patients with few therapeutic choices, antimicrobial resistance in GNB has a major impact on outcomes. There is no single agent BL-BLI with a scope that empirically or specifically encompasses all MDR-GNBs treatment exists as of yet. A serious issue in hospital settings, expanding multidrug protection from Gram-positive diseases, quite those welcomed on by MRSA, VRE, and *S. pneumoniae*, has led to substantial morbidity and death. There will be 43 antibiotics under clinical development by the end of 2020.

FUTURE SCOPE

The progression of science in the impending years will be critical, and keeping in mind that the medications analyzed in this survey are just the start, they are a huge positive development that could really have an effect and empower a

reversal of current evaluations when joined with individual way of behaving and human obligation.

REFERENCES

- [1] Bhavnani, S. M., Krause, K. M., and Ambrose, P. G. (2020). A broken antibiotic market: review of strategies to incentivize drug development. *Open Forum Infect. Dis.* 7 (7), ofaa083. doi:10.1093/ofid/ofaa083.
- [2] Bhavnani, S. M., and Rex, J. H. (2017). Editorial overview: use of PK-PD for antibacterial drug development: decreasing risk and pathos forward for resistant pathogens. *Curr. Opin. Pharmacol.* 38, vii–xii. doi: 10.1018/j.coph.2017.11.008.
- [3] Blot, S.I.; Pea, F.; Lipman, J. The Effect of Pathophysiology on Pharmacokinetics in the Critically Ill Patient--Concepts Appraised by the Example of Antimicrobial Agents. *Adv. Drug Deliv Rev.* 2014, 77, 3–11.
- [4] Drusano, G. L. (2004). Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. *Nat. Rev. Microbiol.* 2, 289–300. doi:10.1038/nrmicro862
- [5] Gallo, J. M. (2010). Pharmacokinetic/pharmacodynamic-driven drug development. *Mt. Sinai J. Med.* 77 (4), 381–388. doi:10.1002/msj.20193
- [6] Griffith, D.C.; Sabet, M.; Tarazi, Z.; Lomovskaya, O.; Dudley, M.N. Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem. *Antimicrob. Agents Chemother.* 2019, 63.
- [7] Improved DWT for Multi-Focus Image Fusion." *International Journal of Science and Research (IJSR)*, vol. 5, no. 5, *International Journal of Science and Research*, May 2016, pp. 1331–33.

- [8] Kaur, Navneet, and Nitish Mahajan. "Image Forgery Detection Using SIFT and PCA Classifiers for Panchromatic Images." *Indian Journal of Science and Technology*, vol. 9, no. 35, Indian Society for Education and Environment, Sept. 2016.
- [9] Luepke and Mohr, J. F. (2017). The antibiotic pipeline: reviving research and development and speeding drugs to market. *Expert Rev. Anti. Infect. Ther.* 15 (5), 425–433. doi:10.1080/14787210.2017.1308251.
- [10] O'Donnell J., Lawrence K., Vishwanathan K., Hosagrahara V., Mueller J.P. Single-dose pharmacokinetics, excretion, and metabolism of Zoliflodacin, a novel spiroprimidinetriene antibiotic, in healthy volunteers. *Antimicrob. Agents Chemother.* 2019;63:e01808. doi: 10.1128/AAC.01808-18.
- [11] Rizk, M. L., Bhavnani, S. M., Drusano, G., Dane, A., Eakin, A. E., Guina, T., et al. (2019). Considerations for dose selection and clinical pharmacokinetics/pharmacodynamics for the development of antibacterial agents. *Antimicrob. Agents Chemother.* 63 (5), e02309–18. Doi:10.1128/AAC.02309-18
- [12] Trivedi, A., Lee, R. E., and Meibohm, B. (2013). Applications of pharmacometrics in the clinical development and pharmacotherapy of anti-infectives. *Expert Rev. Clin. Pharmacol.* 6 (2), 159–170. doi:10.1586/ecp.13.
- [13] Venkataraman, R.; Divatia, J.V.; Ramakrishnan, N.; Chawla, R.; Amin, P.; Gopal, P.; Chaudhry, D.; Zirpe, K.; Abraham, B. Multicenter Observational Study to Evaluate Epidemiology and Resistance Patterns of Common Intensive Care Unit-Infections. *Indian J. Crit Care Med.* 2018, 22, 20–26.
- [14] WHO Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. [(accessed on 1 May 2021)];2016
- [15] Zhang, Yu, et al. "Boundary Finding Based Multi-focus Image Fusion Through Multi-scale Morphological Focus-measure." *Information Fusion*, vol. 35, Elsevier BV, May 2017, pp. 81–101.
- [16] S B G Tilak Babu and Ch Srinivasa Rao, "An optimized technique for copy-move forgery localization using statistical features", *ICT Express*, Volume 8, Issue 2, Pages 244-249, 2022.
- [17] S B G Tilak Babu and Ch Srinivasa Rao, "Efficient detection of copy-move forgery using polar complex exponential transform and gradient direction pattern" , *Multimed Tools Appl* (2022). <https://doi.org/10.1007/s11042-022-12311-6>.
- [18] S. B. G. T. Babu and C. S. Rao, "Statistical Features based Optimized Technique for Copy Move Forgery Detection," 2020 11th Int. Conf. Comput. Commun. Netw. Technol. ICCCNT 2020, 2020.
- [19] Purnachandra Reddy Guntaka, Lankalapalli S. DESIGN AND DEVELOPMENT OF SPRAY DRIED TELAPREVIR FOR IMPROVING THE DISSOLUTION FROM TABLETS. *International Journal of Pharmaceutical, Chemical & Biological Sciences*. Volume 7, 2017.
- [20] Purnachandra Reddy Guntaka, Lankalapalli S. SOLID DISPERSION-A NOVEL APPROACH FOR BIOAVAILABILITY ENHANCEMENT OF POORLY WATER-SOLUBLE DRUGS IN SOLID ORAL DOSAGE FORMS. *Asian Journal of Pharmaceutical and Clinical Research*. 2019 Feb 7:17-26.

